Vandetanib-eluting beads - BTG

Drug Profile

Vandetanib-eluting beads - BTG

Alternative Names: Vandetanib-eluting radiopaque beads

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG; Centre Hospitalier Universitaire Vaudois
  • Developer BTG; UCL Cancer Institute
  • Class Antineoplastics; Bromobenzenes; Fluorobenzenes; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Colorectal cancer; Liver cancer

Most Recent Events

  • 10 Oct 2017 Preclinical trials in Colorectal cancer in United Kingdom before October 2017 (Intra-arterial)
  • 09 Oct 2017 Clinical trials in Colorectal cancer (Metastatic disease) (Intra-arterial) in United Kingdom
  • 09 Oct 2017 Clinical trials in Liver cancer (Second-line therapy or greater) (Intra-arterial) in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top